Healthcare / Diagnostics & ResearchNSE
$541.60
+11.00 (+2.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-761.6M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17.6B
P/E
17.5x
↓EV/EBITDA
8.9x
↓ROE
10.3%
↑Gross Margin
68.8%
↑Debt/Equity
0.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+16.6%
FCF CAGR
—
FCF margin
-9.9%
FCF / Net income
-0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.73B · net income $1.01B · FCF $-761.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.73B | $7.73B | $7.17B | $6.20B | $4.87B |
| Net Income | $1.01B | $1.01B | $776.1M | $568.4M | $621.1M |
| EBITDA | $2.55B | $2.55B | $2.16B | $1.59B | $1.40B |
| EPS | 30.88 | 30.88 | 23.56 | 17.31 | 19.29 |
| Gross Margin | 68.8% | 68.8% | 67.9% | 66.7% | 68.1% |
| Operating Margin | 15.7% | 15.7% | 14.2% | 11.3% | 14.2% |
| Net Margin | 13.1% | 13.1% | 10.8% | 9.2% | 12.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.55 | 0.55 | 0.23 | 0.20 | 0.04 |
| Current Ratio | 2.68 | 2.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-761.6M | $-761.6M | $-393.0M | $-1.70B | $-650.6M |
| Returns | |||||
| ROE | 10.3% | 10.3% | 8.8% | 7.0% | 8.4% |
| Valuation | |||||
| P/E | 17.54 | 17.54 | 31.90 | 36.26 | 25.64 |
| EV/EBITDA | 8.95 | 8.95 | 12.41 | 13.98 | 11.41 |
| P/B | 1.81 | 1.81 | 2.80 | 2.55 | 2.16 |
| Growth & Yield | |||||
| Revenue Growth | 7.8% | 7.8% | 15.7% | 27.2% | — |
| EPS Growth | 31.1% | 31.1% | 36.1% | -10.3% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.9%
EPS terminal req.
$48.06
Spread vs growth
15.2%
5Y implied EPS CAGR
13.5%
EPS terminal req.
$58.15
Spread vs growth
17.6%
10Y implied EPS CAGR
11.7%
EPS terminal req.
$93.65
Spread vs growth
19.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.1%
Start / end P/E
27.3x → 17.8x
EPS bridge
23.56 → 30.88
Residual
-10.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.